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The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment 
Committee (PRAC) has completed its findings from its public hearing on 
fluoroquinolone and quinolone antibiotics incorporating the views of patients, 
healthcare professionals and academics, including our group, which recommended 
restricted use of systemic/inhaled (fluoro)quinolones1.  
 
Quinolone antibiotics were first developed in the 1960s and now account for 29.7 
million antibiotic prescriptions in the United States. In the 1980s fluorine molecules 
were added to facilitate better penetration of tissues (central nervous 
system/musculoskeletal), while enhancing their effectiveness against a range of 
bacterial infections. However, they may also impair mitochondrial function, trigger 
oxidative stress or result in epigenetic changes in tissues2. For many years, the 
regulatory agencies and medical profession were sceptical of reports suggesting that 
a brief course of such antibiotics could mediate long term tissue damage with 
consequent clinical impact. Nonetheless, persistent campaigning by patient groups 
internationally led the US Food and Drug Administration (FDA) in 2008 to announce 
the first of what would be a series of alerts about the serious side effects including 
tendon rupture, musculoskeletal joint pain and irreversible nerve damage3 while in 
2016 the agency accepted the existence of a potentially permanent syndrome; 
fluoroquinolone-associated disability (FQAD)4.  
 
We became increasingly concerned about this issue upon starting a dedicated tertiary 
complex tendon disease clinic in Scotland some 5 years ago. Our practice made clear 
the significant musculoskeletal disabilities evident in FQAD patients, while we 
anecdotally observed that our patients with existing spondyloarthritis occasionally 
report worsening of these symptoms following fluoroquinolones. Importantly, we along 
with others5 have come to recognise that these patients require a multidisciplinary 
approach with input from specialist physiotherapists, rheumatologists, orthopaedic 
surgeons, neurologists, musculoskeletal radiologists and occupational therapists. This 
prompted us to give evidence to the PRAC and highlight the recognise and refer 
mentality that should be adopted for this difficult-to-treat and under-recognised patient 
group.  
 
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recently 
adopted the PRAC recommendations, which will be ratified by the European 
Commission in early 2019. We believe this process and subsequent guidance will 
finally add weight to the scientific evidence surrounding FQAD, providing sufferers 
the recognition they longed and a treatment pathway they were commonly denied. It 
is vital that practising clinicians acknowledge this debilitating drug adverse reaction 
and in doing so recognise and refer to appropriate musculoskeletal or neurological 
specialist services, depending on the predominating symptoms. 
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